Matthew J. Maurer, MS | Authors

WILLIAM D. KEITH,M.D.,INC

6200 WILSHIRE BLVD

SUITE 1111

Articles

DLBCL Trials May Exclude Patients Who Need Novel Therapies Most

December 11, 2017

In this interview we discuss how a short diagnosis-to-treatment interval in newly diagnosed diffuse large B-cell lymphoma is associated with worse outcomes and how this could lead to trials favoring patients with a longer diagnosis-to-treatment interval and better expected outcomes.